Skip to main content
. 2018 Sep 12;33(3):612–624. doi: 10.1038/s41375-018-0253-3

Fig. 8.

Fig. 8

Impact of decreased GNB2 expression or depleted Gnb2 genome in MLL-AML. a, b, c Growth curves (cell numbers) and GNB2 expression values of 3 human MLL-AML cell lines (a NOMO1, b MOLM13, and c THP1) treated with GNB2 shRNA and control scramble shRNA. Each experiment was performed in triplicate. d, e By genome-wide CRISPR-Cas9 screens, read counts of six sgRNAs targeting per exon (exon 1 (d) and 2 (e)) in Gnb2 were measured after a 16-day incubation period to confirm potential oncogenic function of Gnb2 in MLL/AF9-AML